GlassScriptPhysician profile
Amanda Peyser
NPI 1902273741
$4,295.65
in general payments reported to CMS, 2019-2025
22 companies · $2,783 in 2025
The $2,783 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.83 · 2023: $603 · 2024: $889 · 2025: $2,783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,000 · Food and Beverage: $1,753 · Travel and Lodging: $521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,000.00 |
| Food and Beverage | $1,753.39 |
| Travel and Lodging | $521.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $2,665.49 | 2024-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $461.55 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Ardelyx, INC. | $217.17 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $136.66 | 2023-2024 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $130.09 | 2023-2024 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $94.54 | 2023-2024 | Zeposia |
| Abbvie INC. | $88.65 | 2022-2024 | |
| Genzyme Corporation | $87.47 | 2024-2025 | |
| Exact Sciences Corporation | $71.16 | 2023-2024 | Cologuard Collection Kit |
| Janssen Biotech, INC. | $53.10 | 2024 | Stelara, Tremfya, Simponi |
| Merck Sharp & Dohme LLC | $51.67 | 2023-2024 | Dificid |
| Madrigal Pharmaceuticals | $30.25 | 2024 | Resmetirom |
| Intercept Pharmaceuticals, INC. | $26.64 | 2023 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $26.18 | 2024 | Voquezna |
| Evoke Pharma, INC. | $24.71 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $23.54 | 2024 | |
| Redhill Biopharma INC. | $20.99 | 2023 | Talicia, Aemcolo, Movantik |
| Ironwood Pharmaceuticals, INC | $20.39 | 2024 | |
| Amgen INC. | $18.33 | 2023 | Amjevita, Avsola |
| Celltrion USA INC. | $16.89 | 2024 | Vegzelma |
| Lilly USA, LLC | $16.12 | 2024 | Omvoh |
| Nestle Healthcare Nutrition INC. | $14.06 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Peyser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.